Background Stool pathogen testing is recommended as part of the initial evaluation for
patients with new-onset diarrhea on immune checkpoint inhibitors (ICIs), yet its significance …

Results: A total of 72 patients with IMDC were included: 22 in the study group and 50 as
control. Escherichia coli of different pathotypes was observed in 17 patients. Five patients …

Background Immune checkpoint inhibitors (ICPI) are efficacious treatments for advanced
malignancies but can result in immune mediated diarrhea and colitis (IDC). Currently, the …

Background: Immune checkpoint inhibitors (ICIs) have transformed the management of
advanced malignancies but are associated with diarrhea and colitis. The objective of our …

PURPOSE: Enterocolitis is among the leading adverse events associated with immune
checkpoint inhibitors (ICIs). There are limited retrospective data regarding the safety of ICIs …

Background Immune checkpoint inhibitor therapy has significantly improved the outcomes of
various advanced malignancies that were deemed unruly prior to its invention. Immune …

Background The gut microbiome impacts the efficacy of immune checkpoint inhibitor (ICI)
therapy and the development of ICI-mediated diarrhea and/or colitis (IMDC). Antibiotic …

Abstract Background Immune checkpoint inhibitors (ICIs) have improved the outcomes of
cancer patients. However, ICIs often lead to colitis/diarrhea. This study aimed to assess the …

Immune checkpoint inhibitors (ICIs) have shown significant benefit in cancer patients. Their
success, however, is associated with immune-related adverse events (irAEs), which …

Abstract Background Immune checkpoint inhibitors (ICIs) have improved cancer outcomes.
However, immune-related adverse effects are common. The aim was to investigate the …